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Our aim was to assess renal function using as laboratory measurements serum creatinine
and cystatin C concentrations before and after administration of low-osmolarity (nonionic)
iodinated contrast medium in patients with cancer undergoing computed tomography (CT).
Methods
This prospective study included 400 oncologic outpatients. Serum creatinine and cystatin C
concentrations were measured before and 72 h after contrast administration. Glomerular fil-
tration rates (GFRs) were estimated using serum creatinine–based [Modification of Diet in
Renal Disease (MDRD) and Cockroft-Gault and cystatin C based (Larsson) equations. Ex-
ploratory data analysis was performed. The nonparametric Wilcoxon test was used to com-
pare pre and post contrast of test results and estimated clearance. The confidence interval
used in the analysis was 95%.
Results
Compared with the pre-contrast values, the mean serum creatinine concentration was signif-
icantly higher and average GFRs estimated using MDRD and Cockcroft-Gault equations
were significantly lower after the administration of contrast (p <0.001). It was also observed
a significant increase after contrast in the concentration of Cystatin C (p = 0.015). In addition,
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a decrease in GFR estimated using the average Larsson (p = 0.021) was observed between
time points. However, none of the patients presented clinically significant nephropathy.
Conclusions
Assessment using serum creatinine and cystatin C concentrations showed changes in
renal function among patients with cancer undergoing contrast-enhanced CT examination
in this study. No significant renal damage related to the use of low-osmolarity iodinated con-
trast medium of the type and dosage employed in this study was observed. This contrast
medium is thus safe for use in patients with cancer.
Introduction
An increasing number of patients undergo computed tomography (CT), and the use of iodinat-
ed contrast medium is necessary in most cases. CT is a widely used and often readily accessible
tool of great importance, as it aids in the diagnosis of many conditions. However, the use of
contrast medium is associated with risks, particularly in relation to renal function; this practice
may be contributing to an increased incidence of contrast-induced nephropathy (CIN), which
causes acute kidney injury (AKI) [1].
Exposure to contrast medium causes a substantial proportion of hospital-acquired AKI
cases [2]. CIN was first described in the 1970s as the third leading cause of this complication,
surpassed only by surgery and low blood pressure during hospitalisation [3][4]. The incidence
of CIN-induced AKI has remained similar for more than two decades [5].
Based on observations of peak serum creatinine concentrations [8][9][10], CIN is classically
defined as an increase in the serum creatinine concentration of 0.5 mg/dl or25% from baseline
within 48–72 h after the administration of iodinated contrast medium [11][6][12][13][14].
However, serum creatinine alone is not an accurate marker for the diagnosis of AKI because its
extrarenal excretion can be affected by factors such as ethnicity, age, and protein ingestion [15]
[16][17]. Furthermore, recent studies have demonstrated fluctuations in serum creatinine con-
centration in patients not exposed iodinated contrast medium [7][18][19]. These factors indicate
that the development of a more accurate method of diagnosing CIN-induced AKI is needed.
The use of cystatin C, a member of the cysteine proteinase inhibitor protein (cystatin C) su-
perfamily, as a marker of renal function was proposed in 1985, but its routine laboratory use
was only recently evaluated systematically. Cystatin C is a reliable biochemical marker of glo-
merular filtration due to its small size and high isoelectric point, which enable the filtering of
this protein through the glomerular membrane and the reabsorption of a substantial propor-
tion in the proximal tubule, where it is almost entirely catabolised. No non-renal pathway is
known to be capable of eliminating cystatin C, and factors such as inflammatory and infectious
processes do not alter the level of this protein, which depends primarily on glomerular filtra-
tion [20][21][22–27]. Cystatin C is more sensitive than serum creatinine to acute changes in
kidney function and may be useful for the rapid detection of such changes. Preliminary data
have suggested that cystatin C levels peak 24 h after exposure to contrast media, but few data
on variations in these levels or the superiority of cystatin C to serum creatinine in predicting
subsequent major events are available [28][29][30][31].
Contrast agents dose and type may be related to CIN. In addition, patients who have some
factors including salt depletion, dehydration, anemia, age above 70 years, cardiovascular dis-
eases, diabetes mellitus, smoking, and concurrent use of nephrotoxic drugs have more risk of
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CIN. Hyperlipidemia and alcohol consumption may also be associated with CIN [32,33]. Can-
cer patients usually have one or more of these factors, which increases the risk for renal im-
pairment after contrast administration [34]. Few studies to date have evaluated the incidence
of CIN and the use of contrast media for routine outpatient CT procedures (for monitoring,
treatment, and/or restaging purposes) in patients with cancer who have undergone chemother-
apy, radiotherapy, and/or surgery [35][36][37][38]. Studies have documented an incidence of
chronic renal failure around for 6,7% in patients affected by malignancies, including those re-
ceiving dialysis [39]. Although contrast-enhanced CT is an essential tool in oncology, these fac-
tors cannot be ignored, particularly given the general brittleness of patients with cancer. The
safety of clinical practices for this population should be a priority. The aim of this study was to
evaluate the incidence of CIN in cancer outpatients after the administration of low-osmolarity
iodinated contrast media. For a more accurate evaluation of renal function, both serum creati-
nine and cystatin C methods were used.
Patients and Methods
2.1. Study population
This study was submitted to the Ethics Committee in Research of the Hospital AC Camargo
Cancer Center and approved on May 30, 2011 with the number 1549/11. The written consent
form was delivered in writing to all patients by researchers who also gave clarifications to all
participants when they were unable to understand the consent form, only the legal responsible
could sign for them. All children under 18 years of age who were included had the consent ob-
tained by researchers of their legal responsible, no patient was included in the research without
signing consent in writing. This prospective study involved 400 outpatients with cancer who
underwent CT after the injection of low-osmolarity iodinated contrast at the AC Camargo
Center, São Paulo, Brazil, between January 2012 and September 2013. Patients of any age and
gender were considered for inclusion in the study. Pregnant women, patients with histories of
renal failure and haemodialysis or peritoneal dialysis, those who had undergone more than one
contrast-enhanced CT examination in the same week, and those receiving CIN prophylaxis
were excluded. All participants met the imaging department’s selection criteria, which were de-
signed to identify conditions favourable for the injection of contrast medium. The serum creat-
inine concentration< 1.5 mg/dL and no history of allergic reaction to contrast medium were
considered to indicate suitability for the examination. Data on cancer type, histological grade,
location, stage, metastasis, and treatment, as well as the receipt of chemotherapy prior to or
concurrent with contrast-enhanced CT, were collected.
2.2. CT examination and laboratory testing
All tests and CT examinations were performed in the laboratory and imaging department, re-
spectively, of the AC Camargo Cancer Center. All contrast-enhanced CT examinations were
requested by the patients’ physicians for routine purposes, such as staging, follow up, or moni-
toring of disease evolution or remission. No CT examination was performed only for research
purposes. Examinations were performed according to the imaging department’s protocol, with
no additional cost, volume, or risk related to the use of contrast medium associated with this
study. The amount of organically bound low-osmolarity (non-ionic) iodinated contrast (702
mOsm/kg osmolarity, 37°C, 320 mg/ml concentration; Tyco/Mallincrodt) injected was deter-
mined by the patient’s weight (90–125 ml at 1 ml/kg).
Blood samples were collected for serum assays immediately before and 72 h after contrast
administration, when patients were asked to return for this purpose. Serum concentrations of
cystatin C and creatinine were determined by nephelometry and the kinetic Jaffe method,
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respectively, using automated equipment. Established reference values were used in this study
(cystatin C, 0.6–1.0 mg/l; creatinine, 0.6–1.5 mg/dl). Glomerular filtration rates (GFRs) were
estimated using the widely applied Cockcroft-Gault [CG; (140 - age) × weight (kg) / serum cre-
atinine × 72 × (0.85 if female)], Modification of Diet in Renal Disease [MDRD; 175 × serum
creatinine−1.154 × age−0.203 × (0.742 if female)], and Larsson (77.24 × cystatin C−1.2623) equa-
tions [40–42][43]. GFRs were interpreted with reference to the international standards pro-
posed by the National Kidney Foundation of London (NKF 2002), in which were defined, five
stages of chronic kidney disease, ranging from one to five, where one is the mildest form of the
disease and five would be a more severe where hemodialysis is now indispensable to life [15].
For serum creatine adopt the recommendations of the European Society of Urogenital Radiolo-
gy (ESUR) standard, which defines a 25% increase in baseline creatinine or 0.5 mg/dL [14].
Cystatin C was considered to increase 10% from baseline of this marker. These standards
were used to identify CIN [22].
2.3. Statistical analyses
Exploratory data analyses, including the calculation of descriptive statistics, was performed.
The nonparametric Wilcoxon test was used to compare pre- and post-contrast test results and
estimated GFRs. The chi-squared test was used to compare pre- and post-contrast stages of
kidney disease, as defined using GFRs. A 95% confidence interval was used for all analyses. The
Minitab 14 software was used for analysis.
Results
A total of 400 patients aged 14–86 years participated in this study; 227 (56.9%) patients were fe-
male. Patients’ demographic and clinical characteristics are described on Table 1. Thirty-one
(7.8%) patients did not return for post-contrast blood collection and examination results for 10
(4%) patients were incomplete; these patients were excluded from the sample. Pre- and post-
contrast creatinine concentrations were available for 359 patients, allowing GFR estimation
using the CG and MDRD equations; due to the high cost of cystatin C assessment, GFR estima-
tion using the Larsson equation was possible for only 269 patients.
Compared with pre-contrast values, creatinine and cystatin C concentrations were signifi-
cantly higher (p< 0.001 and p = 0.015, respectively) and estimated GFRs were significantly
lower (CG and MDRD, p< 0.001; Larsson, p = 0.021) after contrast administration (Table 2).
Box plots of these parameters (Figs 1 and 2) show several outlying values. Of 359 patients for
whom pre- and post-contrast creatinine concentrations were obtained, CIN was identified in
two (0.56%) patients [95% confidence interval (CI), 0.068–2.00%] based on a 0.5-mg/dl in-
crease and in 33 (9.2%) patients (95% CI, 6.4–12.7%) based on a25% increase from baseline
serum creatinine concentrations. Seventy-five (27.9%; 95% CI, 22.6–33.7%) patients met the
CIN criterion of10% increase in cystatin C concentration [22]. However, only one patient
had an increase of serum creatinine above the established reference values. None of the patients
presented clinically significant CIN, which was defined as development of symptoms related to
renal impairment or need of specific treatment such as dialysis to normalize renal function.
Table 3 shows the distribution of pre- and post-contrast estimated GFRs according to the
stages of kidney disease defined in the NKF 2002 international standards.
Discussion
In this study evaluating cancer patients undergoing CT with the intravenous injection of low-
osmolarity (non-ionic) iodinated contrast, we observed an overall increase in serum creatinine
and cystatin C values after contrast administration. The incidence of CIN was 9.2% when the
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serum creatinine criterion was used, and 27.9% when the cystatin C criterion was used, which
was expected because the last is a more sensitive marker for kidney injury. However, only one
patient had an increase on serum creatinine above the reference value and none presented clin-
ically significant CIN.
The pathophysiology of CIN is not fully understood, but may involve haemodynamic
changes, endothelial vasoactive mediators, aetiological factors, generation of free radicals, or
Table 1. Demographic and clinical characteristics of the included patients (n = 400).
VARIABLES RESULTS
AGE (n = 400)—mean (range) 53,7 years (14–86 years)
GENDER (n = 399)—n(%)
Female 227 (56,9%)
Male 172 (43,1%)
CHEMOTHERAPY (n = 240)—n(%)
No 72 (30,0%)
Yes 168 (70,0%)
RADIOTHERAPY (n = 238)—n(%)
No 150 (63,0%)
Yes 88 (37,0%)
METASTASIS (n = 240)—n(%)
No 102 (42,5%)
Yes 138 (57,5%)
SINGLE KIDNEY (n = 394)—n(%)
No 365 (92,6%)
Yes 29 (7,4%)
HISTOLOGIC TYPE (MORE COMMONS)—n(%)
Colon Adenocarcinoma 29 (12,1%)
Breast Invasive Ductal Carcinoma 29 (12,1%)
Prostate Adenocarcinoma 10 (4,2%)
Rectal Adnocarcinoma 8 (3,4%)
Lung Adenocarcinoma 7 (2,9%)
Renal Carcinoma Cells 6 (2,5%)
Gastric Adenocarcinoma 5 (2,1%)
doi:10.1371/journal.pone.0122877.t001
Table 2. Serum creatinine and cystatin C concentrations and estimated glomerular filtration rates before and after contrast administration.
Variable na Pre-contrast Post-contrast
Mean SD Min Med Max Mean SD Min Med Max p
Creatinine (mg/dl) 359 0.846 0.226 0.380 0.800 2.090 0.881 0.237 0.370 0.830 2.240 <0.001
Cystatin C (mg/l) 269 0.849 0.238 0.460 0.800 1.980 0.866 0.242 0.450 0.820 1.950 0.015
eGFR (MDRD) 359 99.3 29.2 29.0 97.4 291.0 94.8 27.9 32.4 92.2 275.7 <0.001
eGFR (CG) 359 98.1 32.6 23.6 91.9 266.8 94.1 29.7 24.8 88.8 185.0 <0.001
eGFR (Larsson) 269 104.4 32.7 32.6 102.4 205.9 102.1 32.4 33.3 99.2 211.6 0.021
aOnly patients for whom pre- and post-contrast test results were available were included in analyses.
SD = standard deviation, Min = minimum, Med = median, Max = maximum, eGFR = estimated glomerular filtration rate, MDRD = Modification of Diet in
Renal Disease, CG = Cockroft-Gault.
doi:10.1371/journal.pone.0122877.t002
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direct tubular toxicity [44,45]. The incidence of CIN is approximately 2% in the general popu-
lation [10], but it can reach 90% in high-risk patients [11]. Pre-existing risk factors complicat-
ing renal damage may include chronic underlying diseases such as diabetes mellitus, the type
and volume of contrast medium, and the duration of treatment with anti-cancer drugs [46,47]
[37]. We also observed reductions in GFRs calculated using the MDRD and CG equations in
association with the elevation of serum creatinine concentrations.
In an evaluation of 11,588 patients, Bruce et al. [7] observed that the incidence of creatinine
elevation in control subjects undergoing unenhanced CT was statistically similar to that in pa-
tients undergoing CT with low-osmolar or isoosmolar contrast medium. Newhouse et al. [18]
evaluated 32,161 patients who had not received contrast material and reported that more than
half of these patients showed an increase of at least 25% in serum creatinine concentration and
more than two-fifths showed an increase of at least 0.4 mg/dl. Briguori et al. [23] evaluated the
incidence of CIN in 410 consecutive patients with chronic kidney disease undergoing either
coronary and/or peripheral angiography and/or angioplasty, and found an increase0.3mg/dl
Fig 1. Box plots of serum creatinine (a) and cystatin C (b) concentrations before and after contrast
administration.
doi:10.1371/journal.pone.0122877.g001
Fig 2. Box plots of pre- and post-contrast estimated glomerular filtration rates calculated using the
Modification of Diet in Renal Disease MDRD (a), Cockroft-Gault (b), and Larsson (c) equations.
doi:10.1371/journal.pone.0122877.g002
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in serum creatinine on 8.2% and an increase10% in serum cystatin C on 21.2%. We observed
an increase10% in serum cystatin C in 27.9% of our patients, however they developed no
complication indicating the presence of CIN.
Conclusions
Assessment using serum creatinine and cystatin C concentrations showed that there is a mild
impairment in renal function among patients with cancer undergoing contrast-enhanced CT
examination, however, the variation in laboratory measurements occurred within the normal
reference values in almost all patients and no cases of clinically significant CIN was reported in
our sample. These findings indicate that the use of low-osmolarity (non-ionic) iodinated con-
trast at the dosage employed in this study is safe in patients with cancer.
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